MedTrace Logo

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

NCT03747224 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2025-12-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial hypercholesterolemia and severe hypertriglyceridemia.

Conditions

  • Dyslipidemias
  • Familial Hypercholesterolemia
  • Hypertriglyceridemia

Interventions

DRUG

ARO-ANG3

single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections

DRUG

sterile normal saline (0.9% NaCl)

calculated volume to match active treatment

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-07
Primary Completion
2021-05-17
Completion
2021-05-17
FDA Drug
Yes

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03747224 on ClinicalTrials.gov